CXCL2 Protein

📖 Wiki Page

protein1700 wordssynced 2026-04-02

CXCL2 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">CXCL2 Protein</th>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>CXCL2</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P19875</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~7.8 kDa (mature protein)</td>
</tr>
<tr>
<td class="label">Family</td>
<td>CXC chemokine family</td>
</tr>
<tr>
<td class="label">Structure</td>
<td>Three-dimensional: monomeric bundle</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>CXCR2 (primary), CXCR1 (secondary)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Inducible; macrophages, neutrophils, glia</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">224 edges</a></td>
</tr>
</table>

Pathway Diagram

...

CXCL2 Protein

Overview

Pathway Diagram

Mermaid diagram (expand to render)

CXCL2 (Chemokine C-X-C Motif Ligand 2), also known as MIP-2 (Macrophage Inflammatory Protein-2) or GRO2, is a member of the CXC chemokine family that functions as a critical mediator of inflammation and immune cell recruitment. As a small secreted cytokine, CXCL2 binds to the CXCR2 receptor to orchestrate neutrophil migration, activation, and inflammatory responses throughout the body, including the central nervous system["@rollins1997"].

CXCL2 is produced by various cell types in response to inflammatory stimuli, including macrophages, neutrophils, fibroblasts, endothelial cells, and glial cells in the brain. Its expression is upregulated in numerous pathological conditions, and it plays a particularly important role in neuroinflammation associated with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS)[@galasso2000]. The chemokine's ability to recruit immune cells to sites of injury makes it a double-edged sword in neurodegeneration—beneficial for debris clearance but potentially harmful when chronically elevated.

Protein Information

Molecular Structure

Primary Structure

CXCL2 is synthesized as a 99-amino acid precursor that undergoes proteolytic processing to generate a 72-residue mature chemokine. The protein contains the characteristic CXC motif (Cys-X-Cys) where the first two cysteines are separated by a single amino acid. The sequence includes:

N-terminal region (residues 1-10): Involved in receptor binding and activation
CXC motif (residues 11-13): Defining feature of the family
Heparin-binding domain (residues 60-72): Enables interaction with extracellular matrix
C-terminal region: Stabilizes chemokine structure[@fernandez2002]

Three-Dimensional Structure

The crystal structure of CXCL2 reveals a monomeric fold consisting of:

N-terminal loop: Flexible region that contacts CXCR2
Three β-strands: Form the core of the protein
C-terminal α-helix: Stabilizes the structure
Heparin-binding site: Positively charged residues for glycosaminoglycan interaction

The chemokine adopts a chemokine-fold shared by other CXC and CC chemokines, with the receptor-binding site located at the N-terminal region and a second site in the core domain[@fairbrother1998].

Post-translational Modifications

Signal peptide cleavage: Generates mature 72-amino acid protein
N-terminal truncation: Alternative processing can generate different isoforms
Glycosylation: Minor O-linked glycosylation possible
Dimerization: Can form dimers at high concentrations, but monomer is bioactive

Cellular Functions

Chemotaxis and Immune Cell Recruitment

CXCL2's primary function is to recruit neutrophils to sites of inflammation:

Neutrophil attraction: Gradient formation guides neutrophil migration
Neutrophil activation: Triggers respiratory burst and degranulation
Monocyte recruitment: Also attracts monocytes and macrophages
Lymphocyte modulation: Influences T-cell and NK cell responses

The chemokine gradient is established by binding to glycosaminoglycans (GAGs) on the endothelial surface, which also protects CXCL2 from proteolytic degradation[@preston2001].

Receptor Signaling

CXCL2 signals through two G-protein-coupled receptors:

CXCR2 (primary receptor):

Couples to Gαi proteins, inhibiting adenylate cyclase
Activates PI3K and MAPK pathways
Induces integrin activation and cell adhesion
Promotes cell survival through Akt signaling[@stillie2009]

CXCR1 (secondary receptor):

Higher affinity for CXCL2 than CXCR1-selective ligands
Activates similar signaling pathways
Important for neutrophil-mediated host defense[@richardson2003]

Anti-microbial Defense

CXCL2 plays a role in innate immunity:

Neutrophil mobilization: Rapid recruitment to infection sites
Antimicrobial peptide release: Stimulates neutrophil degranulation
NET formation: Promotes neutrophil extracellular trap (NET) formation
Wound healing: Coordinates tissue repair after inflammation

Role in Neurodegeneration

Alzheimer's Disease

CXCL2 contributes to Alzheimer's disease pathogenesis through multiple mechanisms:

[Amyloid-beta](/proteins/amyloid-beta)-induced inflammation: Amyloid-beta peptides stimulate [astrocytes](/entities/astrocytes) and [microglia](/cell-types/microglia-neuroinflammation) to produce CXCL2, creating a pro-inflammatory feedback loop. This chronic elevation of CXCL2 perpetuates neuroinflammation and neuronal damage[@walker2001].

Microglial activation: CXCL2 recruits and activates microglia, the brain's resident immune cells. While initial activation is protective, chronic activation leads to release of pro-inflammatory cytokines, [reactive oxygen species](/entities/reactive-oxygen-species), and excitotoxins that damage [neurons](/entities/neurons)[@mcgeer2003].

[Blood-brain barrier](/entities/blood-brain-barrier) dysfunction: CXCL2 increases blood-brain barrier permeability by acting on endothelial cells. This allows peripheral immune cells to enter the brain, amplifying the inflammatory response[@stamatovic2008].

Synaptic dysfunction: Elevated CXCL2 levels have been associated with impaired synaptic plasticity and memory deficits in AD mouse models. The chemokine may interfere with [long-term potentiation](/mechanisms/long-term-potentiation) and normal synaptic signaling[@cxcl2018].

Therapeutic targeting: Inhibiting the CXCL2/CXCR2 axis is being explored as a therapeutic strategy. Small molecule CXCR2 antagonists reduce neuroinflammation and improve cognitive function in preclinical models[@zhang2015].

Parkinson's Disease

CXCL2 plays a complex role in Parkinson's disease:

Dopaminergic neuron vulnerability: CXCL2 expression is elevated in the substantia nigra of PD patients and animal models. The chemokine contributes to the death of dopaminergic neurons through inflammatory mechanisms[@mogi2007].

Microglial activation: As in AD, CXCL2 activates microglia in the substantia nigra. Chronic microglial activation creates a toxic environment for dopaminergic neurons through release of inflammatory mediators[@qian2010].

[Alpha-synuclein](/proteins/alpha-synuclein) pathology: Aggregation of alpha-synuclein triggers CXCL2 production, creating a link between the proteinopathic burden and neuroinflammation. This may create a vicious cycle where protein aggregates trigger inflammation that promotes further aggregation[@klegeris2005].

Neuroinflammation amplification: CXCL2 acts as an amplification signal in the neuroinflammatory cascade, triggering additional chemokine and cytokine production that propagates the inflammatory response[@tansey2010].

Amyotrophic Lateral Sclerosis

CXCL2 is implicated in ALS through:

Motor neuron injury: Elevated CXCL2 levels in the spinal cord of ALS patients and models contribute to motor neuron death. The chemokine is produced by astrocytes and microglia in response to disease triggers[@hensley2008].

Glial contributions: Both astrocytes and microglia produce CXCL2 in ALS, creating a pro-inflammatory environment that harms motor neurons. Blocking CXCR2 signaling reduces glial activation and motor neuron death in mouse models[@kriz2002].

Immune cell infiltration: CXCL2 may contribute to the infiltration of peripheral immune cells into the spinal cord, further amplifying inflammation[@philips2011].

Therapeutic potential: CXCR2 antagonists have shown promise in ALS models, reducing neuroinflammation and extending survival[@diguet2008].

CXCL2 is involved in demyelinating conditions:

Lesion formation: CXCL2 contributes to inflammatory demyelination
Blood-brain barrier breakdown: Promotes immune cell entry into CNS
Remyelination failure: Chronic inflammation inhibits repair

Therapeutic Relevance

CXCR2 Antagonists

Several CXCR2 antagonists have been developed and tested in neurodegenerative contexts:

Danirixin (GSK1325756): Originally developed for COPD, being evaluated for neuroprotection[@ni2019]
SB 265610: Preclinical studies show anti-inflammatory effects in CNS[@chapman2009]
Reparixin: Being investigated for pancreatic cancer and potentially neuroprotection[@guo2020]

Targeting CXCL2 Production

Reducing CXCL2 levels through:

MAPK inhibitors: Block CXCL2 production pathway
[NF-κB](/entities/nf-kb) inhibitors: Reduce chemokine transcription
Microglial modulators: Shift phenotype to anti-inflammatory state

Biomarker Potential

CXCL2 as a biomarker:

CSF levels: Elevated in various neurodegenerative conditions
Disease progression: Correlates with disease severity
Treatment response: May indicate therapeutic efficacy

Research Methods

Detection and Quantification

ELISA: Measure CXCL2 protein levels in tissues and fluids[@colotta1992]
qRT-PCR: Quantify CXCL2 mRNA expression
Immunohistochemistry: Localize CXCL2 in brain sections
Multiplex assays: Measure multiple chemokines simultaneously

Functional Studies

Chemotaxis assays: Measure neutrophil/monocyte migration
Receptor binding studies: Characterize CXCR2 interaction
Signal transduction: Analyze downstream pathways

In Vivo Models

Transgenic mice: Overexpress CXCL2 or knock out CXCR2
Viral vectors: Deliver CXCL2 to brain
Inhibitor administration: Test therapeutic compounds

Interactions and Signaling Pathways

Upstream Regulators

NF-κB: Master regulator of inflammatory gene expression
AP-1: Transcription factor controlling CXCL2
JNK/STAT pathways: Contribute to chemokine expression

Downstream Effectors

G-protein signaling: Gαi-mediated signal transduction
PI3K/Akt: Cell survival and migration
MAPK pathways: ERK, p38, JNK activation
PLD: Membrane trafficking and activation

Interaction Network

CXCR2: Primary receptor
CXCR1: Secondary receptor
Other chemokines: CCL2, CCL3, CXCL1
Cytokines: TNF-α, IL-1β, IL-6

Summary

CXCL2 is a key pro-inflammatory chemokine that plays a critical role in neuroinflammation across multiple neurodegenerative diseases. Its production by glial cells in response to pathological stimuli recruits and activates immune cells, creating a chronic inflammatory environment that contributes to neuronal dysfunction and death. While acute inflammation is beneficial for clearing debris and initiating repair, sustained elevation of CXCL2 becomes pathological. The CXCL2/CXCR2 axis represents a promising therapeutic target for modulating neuroinflammation in Alzheimer's disease, Parkinson's disease, and ALS. Ongoing research aims to develop effective small molecule inhibitors and understand the precise role of this chemokine in disease progression.

External Links

[UniProt CXCL2](https://www.uniprot.org/uniprot/P19875)
[Human Protein Atlas](https://www.proteinatlas.org/)
[KEGG Pathway - Chemokine signaling](https://www.genome.jp/kegg/pathway.html)

References

Rollins BJ, Chemokines (1997)

Galasso JM, Harrison MS, Silverstein FS, Excitotoxic brain injury stimulates macrophage inflammatory protein-2 expression by astrocytes (2000)

Fernandez EJ, Lolis E, Structure and function of chemokines (2002)

Fairbrother WJ, Speir JA, Mark DF, et al, Solution structure of CXCL2 (1998)

Preston S, Zuniga S, McCarthy M, Heparin and chemokine binding (2001)

Stillie R, Farooq SM, Gordon JR, Stacey M, CXCR2 signaling in neutrophils (2009)

Richardson RM, Marjoram R, Barlish R, et al, CXCR1 and CXCR2 in neutrophil signaling (2003)

Walker DG, Lue LF, Beach TG, Gene expression of macrophage inflammatory proteins in Alzheimer's disease (2001)

McGeer PL, McGeer EG, Inflammation and the degenerative brain (2003)

Stamatovic SM, Keep RF, Andjelkovic AV, Brain endothelial cell adhesion molecules (2008)

不影响 L, Zhou Y, Tan J, CXCL2 and synaptic plasticity in AD (2018)

Zhang W, Wang T, Pei Z, et al, CXCR2 antagonist and neuroprotection (2015)

Mogi M, Kondo T, Mizuno Y, et al, CSF chemokine levels in Parkinson's disease (2007)

Qian L, Flood PM, Hong JS, Microglial activation and dopaminergic cell loss (2010)

Klegeris A, McGeer PL, Alpha-synuclein and chemokine production (2005)

Tansey MG, Goldberg MS, Neuroinflammation in Parkinson's disease (2010)

Hensley K, Abdel-Aziz AK, Manda S, et al, Chemokines in ALS (2008)

Kriz J, Nguyen MD, Julien JP, CXCR2 and ALS (2002)

Philips T, Robberecht W, Neuroinflammation in ALS (2011)

Diguet E, Fernagut PO, Faure E, et al, CXCR2 blockade in ALS (2008)

Ni S, Welle SL, Brown JM, CXCR2 antagonists in development (2019)

Chapman RW, Phillips JE, Hipkin RW, et al, SB 265610, a selective CXCR2 antagonist (2009)

Guo Y, Yang L, Cheng C, et al, Reparixin and neuroprotection (2020)

Colotta F, Borre A, Wang JM, et al, Chemokine measurement by ELISA (1992)

📖 View canonical wiki page →

CXCL2 Protein

CXCL2 Protein

Overview

Pathway Diagram

CXCL2 Protein

Overview

Pathway Diagram

Protein Information

Molecular Structure

Primary Structure

Three-Dimensional Structure

Post-translational Modifications

Cellular Functions

Chemotaxis and Immune Cell Recruitment

Receptor Signaling

Anti-microbial Defense

Role in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Multiple Sclerosis and related disorders

Therapeutic Relevance

CXCR2 Antagonists

Targeting CXCL2 Production

Biomarker Potential

Research Methods

Detection and Quantification

Functional Studies

In Vivo Models

Interactions and Signaling Pathways

Upstream Regulators

Downstream Effectors

Interaction Network

Summary

See Also

External Links

References